FindTrial
Sign In

AC

BEHAVIORAL5 trials

Sponsors

Brown University, Hoffmann-La Roche, Mỹ Đức Hospital, Cynthia Conklin, University of Washington

Conditions

Alzheimer's DiseaseBreast CancerCircadian DysrhythmiaCognitive DeclineCognitive ImpairmentCritical IllnessDeliriumDementia

Phase 1

A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer
CompletedNCT03800836
Hoffmann-La RocheBreast Cancer
Start: 2018-02-13End: 2022-03-16Updated: 2024-10-30

Phase 2

Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer.
CompletedNCT02789657
Brown UniversityBreast Cancer
Start: 2016-11-21End: 2020-03-27Updated: 2022-05-19

Unknown Phase

Natural Cycle vs. Modified Natural Cycle vs. Artificial Cycle Protocol for Endometrial Preparation.
CompletedNCT04804020
Mỹ Đức HospitalFrozen Embryo Transfer, IVF
Start: 2021-03-22End: 2023-12-31Updated: 2024-07-29
AAT + tDCS to Reduce Cue-induced Craving and Smoking Behavior
CompletedNCT05426460
Cynthia ConklinSmoking Behaviors, Smoking, Cigarette
Start: 2022-04-29End: 2024-06-14Updated: 2025-07-10
A Multi-Modal Combination Intervention to Promote Cognitive Function in Older Intensive Care Unit Survivors
RecruitingNCT06411561
University of WashingtonAlzheimer's Disease, Circadian Dysrhythmia, Cognitive Decline +5
Start: 2024-12-26End: 2027-05-31Target: 100Updated: 2025-07-20

Related Papers

O-206 Natural, modified natural or artificial endometrial preparation strategies for frozen embryo transfer in ovulatory women (MONART): a randomized controlled trial
Human Reproduction2024-07-01
Livebirth rate after one frozen embryo transfer in ovulatory women starting with natural, modified natural, or artificial endometrial preparation in Viet Nam: an open-label randomised controlled trial.
2024-06-2619 citations
First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results
Clinical Cancer Research2023-12-0745 citations
Rationale and design of the CRAFT (Continuous ReAssessment with Flexible ExTension in Rare Malignancies) multicenter phase II trial
ESMO Open2021-11-1910 citations
Neoadjuvant weekly paclitaxel and carboplatin with trastuzumab and pertuzumab in HER2-positive breast cancer: a Brown University Oncology Research Group (BrUOG) study.
2021-06-042 citations
Abstract PS12-28: Phase 1b study evaluating a triplet combination of ipatasertib (IPAT), atezolizumab, and a taxane as first-line therapy for locally advanced/metastatic triple-negative breast cancer (TNBC)
Cancer Research2021-02-1512 citations
Abstract PD14-03: Molecular mechanism of ipatasertib (IPAT) and its combination with atezolizumab (atezo) in patients (pts) with locally advanced/metastatic triple-negative breast cancer (aTNBC)
Cancer Research2021-02-151 citations
Phase 1b study evaluating a triplet combination of ipatasertib (IPAT), atezolizumab (Atezo), and paclitaxel (PAC) or nab-PAC as first-line (1L) therapy for locally advanced/metastatic triple-negative breast cancer (aTNBC)
Geburtshilfe und Frauenheilkunde2020-07-014 citations
Phase 1b study evaluating a triplet combination of ipatasertib (IPAT), atezolizumab (Atezo), and paclitaxel (PAC) or nab-PAC as first-line (1L) therapy for locally advanced/metastatic triple-negative breast cancer (aTNBC)
Senologie - Zeitschrift für Mammadiagnostik und -therapie2020-06-013 citations
Abstract CT049: Phase Ib study evaluating a triplet combination of ipatasertib (IPAT), atezolizumab (atezo), and paclitaxel (PAC) or nab-PAC as first-line (1L) therapy for locally advanced/metastatic triple-negative breast cancer (TNBC)
Cancer Research2019-07-0147 citations
Abstract CT049: Phase Ib study evaluating a triplet combination of ipatasertib (IPAT), atezolizumab (atezo), and paclitaxel (PAC) or nab-PAC as first-line (1L) therapy for locally advanced/metastatic triple-negative breast cancer (TNBC)
Clinical Trials2019-07-012 citations